Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The outgoing CEO is the Dutchman Onno van de Stolpe and his replacement is Paul Stoffels, effective April 1, 2022.